Grail Stock Jumps as FDA Papers Signal Galleri Panel Path
FDA posted Galleri briefing papers with no leftover lab-test questions. Panel meets Sept. 23; approval odds remain in focus.
/ 8 items
#GRAL↓
FDA to Review GRAIL’s Galleri Multi-Cancer Blood Test at September Advisory Meeting
GRAIL’s Galleri cancer blood test will be reviewed by FDA experts as the company seeks full approval for early cancer detection.
ASCO 2026: Why Experts Say Galleri Multi-Cancer Test Isn’t Ready Yet
At ASCO 2026, Grail’s Galleri multi-cancer blood test showed promise but missed its main goal in the large NHS trial. Experts say it’s not ready for broad population screening yet.
TD Cowen Turns Bullish on Grail: Upgrade to Buy After 60% Plunge Creates Bargain Entry
TD Cowen upgrades Grail to Buy from Hold with $65 target after 60% selloff. Analyst sees attractive entry in multi-cancer detection despite NHS study miss.
GRAIL Tumbles as NHS-Galleri Trial Fails Primary Endpoint
GRAIL shares plunged 38% after hours despite promising NHS-Galleri trial results. The blood test missed its main goal but cut late-stage cancers and boosted early detection 4x.
Hims Adds Cancer Detection Test to Labs Product
Hims & Hers partners with Grail to offer discounted Galleri cancer detection tests through its Labs subscription service, expanding beyond weight-loss treatments.